These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 19727029)
41. Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function. Hinkle RT; Donnelly E; Cody DB; Bauer MB; Isfort RJ Endocrinology; 2003 Nov; 144(11):4939-46. PubMed ID: 12960070 [TBL] [Abstract][Full Text] [Related]
42. Muscle characteristics in patients with chronic systemic inflammation. Beenakker KG; Duijnisveld BJ; Van Der Linden HM; Visser CP; Westendorp RG; Butler-Brown G; Nelissen RG; Maier AB Muscle Nerve; 2012 Aug; 46(2):204-9. PubMed ID: 22806369 [TBL] [Abstract][Full Text] [Related]
43. The molecular basis of skeletal muscle atrophy. Jackman RW; Kandarian SC Am J Physiol Cell Physiol; 2004 Oct; 287(4):C834-43. PubMed ID: 15355854 [TBL] [Abstract][Full Text] [Related]
44. Role of ATF4 in skeletal muscle atrophy. Adams CM; Ebert SM; Dyle MC Curr Opin Clin Nutr Metab Care; 2017 May; 20(3):164-168. PubMed ID: 28376050 [TBL] [Abstract][Full Text] [Related]
50. Nuclear factor-kappa B signaling in skeletal muscle atrophy. Li H; Malhotra S; Kumar A J Mol Med (Berl); 2008 Oct; 86(10):1113-26. PubMed ID: 18574572 [TBL] [Abstract][Full Text] [Related]
51. Disuse-induced skeletal muscle atrophy in disease and nondisease states in humans: mechanisms, prevention, and recovery strategies. Nunes EA; Stokes T; McKendry J; Currier BS; Phillips SM Am J Physiol Cell Physiol; 2022 Jun; 322(6):C1068-C1084. PubMed ID: 35476500 [TBL] [Abstract][Full Text] [Related]
52. cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration. Berdeaux R; Stewart R Am J Physiol Endocrinol Metab; 2012 Jul; 303(1):E1-17. PubMed ID: 22354781 [TBL] [Abstract][Full Text] [Related]
53. Cytokine Signaling in Skeletal Muscle Wasting. Zhou J; Liu B; Liang C; Li Y; Song YH Trends Endocrinol Metab; 2016 May; 27(5):335-347. PubMed ID: 27025788 [TBL] [Abstract][Full Text] [Related]
54. Signaling in muscle atrophy and hypertrophy. Sandri M Physiology (Bethesda); 2008 Jun; 23():160-70. PubMed ID: 18556469 [TBL] [Abstract][Full Text] [Related]
55. Molecular mechanisms and treatment options for muscle wasting diseases. Rüegg MA; Glass DJ Annu Rev Pharmacol Toxicol; 2011; 51():373-95. PubMed ID: 20936944 [TBL] [Abstract][Full Text] [Related]
56. Skeletal Muscle Disuse Atrophy and the Rehabilitative Role of Protein in Recovery from Musculoskeletal Injury. Howard EE; Pasiakos SM; Fussell MA; Rodriguez NR Adv Nutr; 2020 Jul; 11(4):989-1001. PubMed ID: 32167129 [TBL] [Abstract][Full Text] [Related]
57. Nutritional Considerations in Preventing Muscle Atrophy. Cretoiu SM; Zugravu CA Adv Exp Med Biol; 2018; 1088():497-528. PubMed ID: 30390267 [TBL] [Abstract][Full Text] [Related]
58. Weak by the machines: muscle motor protein dysfunction - a side effect of intensive care unit treatment. Friedrich O; Diermeier S; Larsson L Acta Physiol (Oxf); 2018 Jan; 222(1):. PubMed ID: 28387014 [TBL] [Abstract][Full Text] [Related]
59. Muscle Changes During Atrophy. Dumitru A; Radu BM; Radu M; Cretoiu SM Adv Exp Med Biol; 2018; 1088():73-92. PubMed ID: 30390248 [TBL] [Abstract][Full Text] [Related]
60. Myonuclear domains in muscle adaptation and disease. Allen DL; Roy RR; Edgerton VR Muscle Nerve; 1999 Oct; 22(10):1350-60. PubMed ID: 10487900 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]